Slowing the Pace of Parkinson’s
Researchers explore a small molecule with the potential to tackle disease progression
Maryam Mahdi |
This article was published in our sister publication, The Small Molecule Manufacturer, which celebrates the field of small molecule drug development and manufacturing with interviews and articles focusing on success stories, equipment, and new processing techniques. Read more about The Small Molecule Manufacturer here https://themedicinemaker.com/manufacture/small-but-never-forgotten
A team, led by Matthew Disney from Scripps Research and M. Maral Mouradian from the Rutgers Robert Wood Johnson Medical School Institute for Neurological Therapeutics, has developed a small molecule drug, dubbed Synucleozid, which targets the messenger RNA (mRNA) of ɑ-synuclein, a protein whose misfolding is genetically and neuropathologically linked to Parkinson’s disease (PD) (1). Though there are several experimental treatments in development that target ɑ-synuclein protein aggregates, the team’s goal is to prevent them from developing entirely by inhibiting its translation at the mRNA stage.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.